168 related articles for article (PubMed ID: 19461173)
1. [Malignant lymphomas].
Yamaguchi Y; Usui N
Gan To Kagaku Ryoho; 2009 May; 36(5):736-41. PubMed ID: 19461173
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma.
Inwards DJ; Cilley JC; Winter JN
Best Pract Res Clin Haematol; 2006; 19(4):669-84. PubMed ID: 16997176
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy in malignant lymphoma.
Coiffier B
Oncogene; 2007 May; 26(25):3603-13. PubMed ID: 17530014
[TBL] [Abstract][Full Text] [Related]
5. Current controversies in follicular lymphoma.
Aurora V; Winter JN
Blood Rev; 2006 Jul; 20(4):179-200. PubMed ID: 16410034
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas.
Cilley J; Winter JN
Haematologica; 2006 Jan; 91(1):114-20. PubMed ID: 16434379
[TBL] [Abstract][Full Text] [Related]
7. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.
Seyfarth B; Josting A; Dreyling M; Schmitz N
Br J Haematol; 2006 Apr; 133(1):3-18. PubMed ID: 16512824
[TBL] [Abstract][Full Text] [Related]
8. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
10. Epratuzumab in the therapy of oncological and immunological diseases.
Goldenberg DM
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1341-53. PubMed ID: 17069520
[TBL] [Abstract][Full Text] [Related]
11. Pretargeted radioimmunotherapy for B-cell lymphomas.
Green DJ; Pagel JM; Pantelias A; Hedin N; Lin Y; Wilbur DS; Gopal A; Hamlin DK; Press OW
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5598s-5603s. PubMed ID: 17875795
[TBL] [Abstract][Full Text] [Related]
12. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal antibodies for lymphomas and leukemias in 2005].
Peffault de Latour R; Robin M; Bay JO
Bull Cancer; 2006 Jan; 93(1):107-18. PubMed ID: 16455513
[TBL] [Abstract][Full Text] [Related]
14. [Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
Visser OJ; Zijlstra JM; van Dongen GA; Huijgens PC
Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2324-8. PubMed ID: 16261710
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
16. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Wang Y; Chang CH
Cancer Res; 2008 Oct; 68(20):8384-92. PubMed ID: 18922911
[TBL] [Abstract][Full Text] [Related]
17. Secondary malignancies and quality of life after stem cell transplantation.
Ortega JJ; Olivé T; de Heredia CD; Llort A
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S83-7. PubMed ID: 15812538
[TBL] [Abstract][Full Text] [Related]
18. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
20. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
